Physician

Omid Fatemi, M.D.

According to 2025 Medicare claims, Omid Fatemi, M.D. (NPI: 1326293143) practices interventional cardiology in the Oxnard-Thousand Oaks-Ventura, CA market, with the plurality of this provider's patient population coming from Ventura, CA. This provider's primary affiliated billing organization is CARDIOLOGY ASSOCIATES MEDICAL GROUP (NPI: 1376641449; TIN: 770550705) and primary practice location at 93003-2836. Fatemi is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Fatemi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,516 traditional Medicare patients, billed 8,316 HCPCS/CPT codes, and received $1,218,199 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 4,815 prescription claims across 963 beneficiaries totaling $840,810 in drug costs, led by Eliquis (Apixaban). 2017 DME data shows 11 claims. Open Payments data shows 124 records totaling $473,423. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $96,952 to $1,218,199. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,322 to $840,810. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	374	1,104	$96,952
2016	919	3,965	$387,276
2017	1,007	4,410	$426,091
2018	937	3,966	$375,823
2019	1,071	4,590	$584,407
2020	1,071	5,046	$723,082
2021	1,238	6,560	$930,240
2022	1,333	7,487	$1,003,547
2023	1,523	8,821	$1,074,891
2024	1,516	8,316	$1,218,199

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	31	83	$3,322
2016	210	1,432	$89,458
2017	281	2,063	$171,616
2018	377	2,222	$212,439
2019	535	2,662	$324,660
2020	661	3,506	$461,962
2021	819	4,293	$659,557
2022	924	5,169	$924,027
2023	983	5,502	$1,040,229
2024	963	4,815	$840,810

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	11	$145
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	191	204	$150
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	782	837	$140
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	305	341	$107
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	510	544	$12
99152	Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes	204	223	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	503	27,064	$524,255
Xarelto	Rivaroxaban	89	6,600	$116,422
Entresto	Sacubitril/Valsartan	73	3,335	$73,340
Farxiga	Dapagliflozin Propanediol	21	1,110	$20,542
Rosuvastatin Calcium	Rosuvastatin Calcium	457	39,952	$7,106

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	105	$9,706	Edwards Lifesciences Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	19	$463,717	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Omid Fatemi, M.D.?

Tedicare shows public-source Medicare data for Omid Fatemi, M.D. (NPI 1326293143), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Omid Fatemi, M.D. have ACO affiliation data?

Omid Fatemi, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Omid Fatemi, M.D.?

Omid Fatemi, M.D. is linked to CARDIOLOGY ASSOCIATES MEDICAL GROUP (billing NPI 1376641449) in the available physician profile data.

Does Omid Fatemi, M.D. have Open Payments data?

Omid Fatemi, M.D. has 124 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.